CHAMPIONS ONCOLOGY, INC. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
For fiscal year ended April 30, 2026, Champions Oncology reported record annual revenue of $59.4M (up 4% YoY from $56.9M), with Q4 revenue of $13.8M (up 12% YoY). The company achieved adjusted EBITDA of $1.6M for the year and positive adjusted EBITDA in all four quarters (Q4: $158k vs. loss of $1.2M in prior year). However, GAAP operating income swung to a loss of $1.1M from income of $4.6M, primarily due to absence of $4.5M non-recurring data licensing revenue from prior year and $3.0M in temporary outsourced radiopharmaceutical costs. Q4 oncology services margin was 51% (vs. 41% prior year); full-year margin was 48% (vs. 50%). Cash position declined to $4.9M from $9.8M; no debt.
Why this rating
Record revenue and four quarters of positive adjusted EBITDA are operationally positive for a $15.4M market-cap micro-cap. However, GAAP profitability deteriorated sharply, margin compression ongoing, and cash declined 50%. Strategic investments ongoing but not yet proven. Material for company size but not transformational.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.